Trials / Completed
CompletedNCT06734208
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
A Phase 1, Open-Label, Single-Dose, Parallel-Cohort Study to Evaluate the Pharmacokinetics of Divarasib in Subjects With Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Divarasib | Divarasib will be administered as a single oral dose as specified for the respective cohort. |
Timeline
- Start date
- 2025-01-31
- Primary completion
- 2025-11-27
- Completion
- 2025-11-27
- First posted
- 2024-12-16
- Last updated
- 2025-12-04
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06734208. Inclusion in this directory is not an endorsement.